PATENT APPLICATION

TECH CENTER IGORAGO

01997.001700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

W.		1 -	nlia	ation	· of:	
MI	re	Ap	pnc	atior	1 01.	

ANJANA RAO et al.

Application No.: 10/058,024

Filed: January 29, 2002

For:

**ANERGY-REGULATED** 

( . i

MOLECULES

July 22, 2003

Examiner: Not Yet Assigned

Group Art Unit: 1645

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

The listed documents were cited in a Search Report issued for the international application corresponding to the above-identified application. A copy of the Search Report is enclosed for the Examiner's convenience.

## STATEMENT UNDER 37 C.F.R. § 1.97(e)

Each item of information in this information disclosure statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Statement.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such

information has been considered.

It is believed that no fee is required for consideration of the presently submitted information. However, should a fee be required, the Commissioner is hereby authorized to deduct such a fee from deposit Account No. 06-1205.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

Raymond R. Mandra Attorney for Applicants

Registration No. 34,382

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza

New York, New York 10112-3801

Facsimile: (212) 218-2200

				<del></del>							
FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE E JC.			ATTY DOCKET NO. 01997.001700		PPLICATION NO. 10/058,024						
PATEN	IT AND TRADEMARK	OFFICE 30	APPLICANT ANJANA RAO et al.								
LIST OF REFERENCES CITED BY APPLICANT(S) 2013 (Use several sheets if necessary) 111 2					GROUP	UP 1645					
		Tro Care			1043						
	U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS  VI 25 - 2003	FILING DATE IF APPROPRIATE					
					C	·,					
				ECH,	25						
1				4	NED 1003	·					
					100/20						
		FO	REIGN PATENT DOCUMENTS		~~						
	DOCUMENT NUMBER	DATE	COUNTRY	CLAS	s I SUBCLASSI	TRANSLATION YES/NO/ OR ABSTRACT					
wo	99/40930	08.19.99	International								
		OTHER DOCUMENT(S	) (Including Author, Title, Date, Pertinent Pages, Etc.)								
R. Glynne et al. "How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis", Nature (February 2000); vol. 403, pp. 672-76.											
	F. Macian et al., "Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun", The EMBO Journal (2000), vol. 19, no. 17, pp. 4783-95.										
EXAMINER			DATE CONSIDERED								

Sheet 1 of 1

Form #62

NY\_MAIN 364157v1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.